Publications

Publications

Age, obesity, medical comorbidities and surgical technique are predictive of symptomatic anastomotic strictures after contemporary radical prostatectomy.

By:
Contributors: Geoffrey Gotto, MD
J Urol. 2011 Jun;185(6):2148-52. doi: 10.1016/j.juro.2011.02.003. Epub 2011 Apr 15.

Abstract

PURPOSE:

Anastomotic strictures are relatively common after radical prostatectomy and are associated with significant morbidity, often requiring multiple surgical interventions. There is controversy in the literature regarding which factors predict the development of anastomotic strictures. In this study we determined predictors of symptomatic anastomotic strictures following contemporary radical prostatectomy.

MATERIALS AND METHODS:

Between 1999 and 2007, 4,592 consecutive patients underwent radical prostatectomy without prior radiotherapy at our institution. Data were collected from prospective surgical and institutional morbidity databases, and retrospectively from inpatient and outpatient medical and billing records. Cases were assigned a Charlson score to account for comorbidities. Complications were graded according to the modified Clavien classification.

RESULTS:

Open radical prostatectomy was performed in 3,458 men (75%) and laparoscopic radical prostatectomy was performed in 1,134 (25%). The laparoscopic radical prostatectomy group included 97 robotic-assisted cases. Median patient age was 59.5 years (IQR 54.7, 64.2). Symptomatic anastomotic strictures developed in 198 patients (4%) after a median postoperative followup of 3.5 months (IQR 2.1, 6.1). On multivariate analysis significant predictors included patient age, body mass index, Charlson score, renal insufficiency, individual surgeon, surgical approach and the presence of postoperative urine leak or hematoma.

CONCLUSIONS:

Patient factors as well as technical factors influence the development of symptomatic anastomotic strictures following contemporary radical prostatectomy. The impact of these factors is influenced by the individual surgeon and the approach used.

 

PubMed

Download PDF

Stay Informed

To stay up to date on all the latest news and publications, subscribe to our newsletter!

Clinical Validation Trial of ClarityDX Prostate, a made-in-Alberta blood test to improve the diagnosis of Prostate Cancer

John Lewis will be presenting a seminar entitled “Clinical Validation Trial of ClarityDX Prostate, a made-in-Alberta blood test to improve the diagnosis of Prostate Cancer” at the University of Alberta Urology Grand Rounds this Friday, Feb 8, at the NAUC Auditorium. Please come out and join us for this early morning seminar, your presence is appreciated!
John will discuss the progress in the discovery and clinical validation of novel biomarkers for prostate cancer detection and prognosis. He will also give an overview of the Alberta Prostate Cancer Registry and Biorepository recruitment and future plans, and an overview and goals of the upcoming ClarityDX Prostate blood test clinical validation trial.
Date: Friday, February 8, 2019
Time: 7:00 am – 8:00 am
Location: NAUC Auditorium (7th floor) in the Kaye Edmonton Clinic
See you on Friday!

- Unknown